Blood Screening and Typing Market Size, Share, Growth, and Industry Analysis, By Types (Nucleic Acid Amplification Technology, Immunohematology, Microbiological Technique), By Applications Covered (Reference Laboratories, Standalone Blood Banks, Hospitals), Regional Insights and Forecast to 2035

Blood Screening and Typing Market Size

The Blood Screening and Typing Market is expected to grow from USD 7.49 billion in 2025 to USD 7.70 billion in 2026, reaching USD 7.91 billion in 2027 and expanding to USD 9.87 billion by 2035, at a CAGR of 2.8% during 2026–2035. Growth is driven by rising blood transfusion demand, increasing surgical procedures, and strict blood safety regulations. Technological advancements in automated screening systems and growing healthcare infrastructure in emerging regions further support sustained market expansion.

The U.S. Blood Screening and Typing Market holds a significant share, driven by advanced healthcare infrastructure and stringent regulatory standards. Increasing demand for safe blood transfusions in hospitals and laboratories fuels market growth.

The global blood screening and typing market is expanding due to increasing safety standards in blood transfusions and technological advancements. Nucleic Acid Amplification Testing (NAT) leads the market, accounting for around 70% of all blood screening procedures due to its high sensitivity in detecting viral infections. Immunohematology techniques contribute approximately 20% of the market share, essential for blood typing and compatibility testing. Microbiological techniques, such as bacterial screening for platelets, represent about 10% of the market. Regionally, North America holds the largest share at 40%, driven by robust healthcare infrastructure and stringent regulatory frameworks. The Asia-Pacific region is experiencing rapid growth, contributing to roughly 30% of the market share, spurred by increasing investments in healthcare and a growing population base. Overall, technological advancements, particularly in NAT and immunohematology, are key drivers of the market's growth.

Blood Screening and Typing Market Trends

The blood screening and typing market is marked by several key trends, including technological advancements and an increase in blood transfusion safety standards. Approximately 70% of the market is driven by Nucleic Acid Amplification Testing (NAT), providing highly sensitive screening for infectious diseases. Immunohematology methods account for 20%, playing a vital role in blood typing and cross-matching in transfusions. Microbiological screening techniques are growing, contributing around 10% to the market. The reagent and kit segment leads with 60%, while instruments make up 30% and services account for the remaining 10%. The North American market remains the largest, holding 40% of the market share, followed by the Asia-Pacific region, which is expanding rapidly, contributing approximately 30%. These trends indicate growing adoption of advanced diagnostic technologies in blood screening and typing applications, particularly in high-demand regions like Asia-Pacific and North America.

Blood Screening and Typing Market Dynamics

The blood screening and typing market is primarily driven by the rising incidence of chronic diseases and the demand for safe blood transfusions. Hospitals account for the largest share of the market, representing about 50% of total demand, as they require blood screening technologies to ensure patient safety during procedures. Reference laboratories follow with 30% of the market share, providing specialized screening services for infectious diseases. Standalone blood banks contribute approximately 20% of the market, focusing on blood donations and blood bank operations. Regulatory standards such as mandatory NAT screening for blood donors are impacting market dynamics by ensuring higher safety but also raising costs. Innovations such as fully automated blood typing systems are growing in popularity, meeting the rising demand for accurate and efficient testing. The Asia-Pacific region continues to drive market expansion, contributing around 30% of global demand due to the region’s rapid healthcare development.

DRIVER

"Rising incidence of blood-borne diseases and infections"

The increasing incidence of blood-borne diseases and infections, such as HIV, hepatitis, and malaria, is a major driver of the blood screening and typing market. As these diseases spread globally, there is a heightened need for reliable and efficient blood screening techniques to ensure the safety of blood donations and transfusions. The growing focus on improving the quality of blood products in hospitals, blood banks, and other healthcare facilities is driving the adoption of advanced technologies like nucleic acid amplification and immunohematology. The increasing awareness and implementation of safety measures in healthcare are further contributing to the demand for these solutions.

RESTRAINTS

"High cost of advanced blood screening technologies"

The high cost of advanced blood screening and typing technologies is a significant restraint to market growth. Nucleic acid amplification technology (NAAT) and immunohematology techniques, while offering high accuracy, require sophisticated equipment, skilled personnel, and regular maintenance, which increases the overall cost. This can be a challenge, particularly in developing countries where healthcare budgets are limited. Additionally, the expensive nature of these systems can hinder widespread adoption in smaller or resource-constrained medical facilities. As a result, the affordability of advanced blood screening technologies remains a critical issue that affects market expansion, especially in emerging economies.

OPPORTUNIT

"Advancements in blood screening technologies"

Advancements in blood screening technologies present significant opportunities for market growth. New techniques, such as multiplex PCR (polymerase chain reaction) and next-generation sequencing (NGS), offer greater sensitivity and specificity in detecting pathogens in blood samples. These technologies can significantly improve the accuracy of blood typing and screening, leading to better outcomes in blood transfusions and organ transplants. As the healthcare sector continues to invest in innovative technologies to improve diagnostic accuracy and safety, the blood screening and typing market is expected to see significant growth. Additionally, the ongoing focus on improving donor screening methods in hospitals and blood banks presents further opportunities for innovation.

CHALLENGE

"Regulatory challenges and standardization"

One of the key challenges in the blood screening and typing market is the complex regulatory landscape and the lack of standardization across different regions. Blood screening methods and technologies must meet rigorous regulatory requirements, which can vary between countries. The lack of global standardization in blood typing and screening procedures complicates the approval process and delays the introduction of new technologies. Additionally, different countries may have varying guidelines regarding the safety and efficacy of blood testing products, making it challenging for manufacturers to enter multiple markets. Regulatory hurdles and the need for consistent guidelines across regions remain a significant barrier to the market’s growth.

Segmentation Analysis

The blood screening and typing market is segmented by type and application. By type, the market includes nucleic acid amplification technology, immunohematology, and microbiological techniques. These different techniques are used for detecting infections, typing blood, and ensuring the safety of blood products. The market is also segmented by application, with reference laboratories, standalone blood banks, and hospitals being the primary users of blood screening technologies. These segments are driven by different needs, such as ensuring the safety of blood donations, providing accurate diagnostic results, and offering blood typing services in hospitals and clinics. Understanding the specific needs of each segment is crucial for market growth.

By Type

• Nucleic Acid Amplification Technology: Nucleic acid amplification technology (NAAT) is used to detect the presence of viral or bacterial DNA or RNA in blood samples. This technology is highly sensitive and allows for the detection of infections at early stages, improving blood safety during transfusions. NAAT is commonly used in reference laboratories and blood banks to screen blood donations for pathogens like HIV, hepatitis B, and hepatitis C. The adoption of NAAT is expected to grow due to its ability to provide accurate and timely results. As the demand for more reliable and efficient blood screening techniques increases, NAAT is becoming a critical tool in blood safety.
• Immunohematology: Immunohematology is the study of antigens and antibodies in blood, used primarily for blood typing and crossmatching in blood transfusions. This technique is vital in ensuring compatibility between donors and recipients, reducing the risk of transfusion reactions. Immunohematology is widely used in hospitals, blood banks, and transfusion centers to ensure safe blood transfusions. The growing need for blood compatibility testing, particularly in emergency situations and surgeries, is driving the demand for immunohematology techniques. The technology is expected to continue evolving with advancements in automation and high-throughput systems, improving accuracy and efficiency in blood typing and crossmatching processes.
• Microbiological Technique: Microbiological techniques, including culturing and serology, are used to identify and analyze microorganisms in blood samples. These methods are critical for detecting bacterial or fungal infections in blood, particularly in immunocompromised patients. Microbiological screening techniques help identify pathogens that may not be detected by other blood screening methods, ensuring blood products are safe for transfusion. Although newer technologies like NAAT have gained traction, microbiological techniques remain essential for comprehensive blood safety, especially in hospitals and intensive care units. The need for these methods in diagnosing infections and ensuring blood safety will continue to drive the adoption of microbiological techniques in blood screening.

By Application

• Reference Laboratories: Reference laboratories play a crucial role in the blood screening and typing market, providing diagnostic testing and analysis of blood samples from hospitals, clinics, and other healthcare settings. These laboratories are equipped with advanced technology to conduct high-volume screenings and offer specialized services, including molecular diagnostics and pathogen detection. As the demand for accurate blood screening increases, reference laboratories are expanding their services to meet the needs of healthcare providers. The increasing complexity of blood screening procedures and the need for specialized expertise are driving the growth of reference laboratories as a key application segment in the market.
• Standalone Blood Banks: Standalone blood banks are specialized centers that collect, store, and distribute blood and blood products. These centers require advanced blood screening technologies to ensure the safety and compatibility of blood donations. Blood banks use various blood typing and pathogen screening techniques to test the blood before it is distributed to hospitals and clinics. The rising demand for safe and compatible blood donations, particularly in regions with high disease prevalence, is driving the growth of standalone blood banks. As safety standards become stricter and the need for blood donations increases, the demand for advanced blood screening technologies in blood banks continues to rise.
• Hospitals: Hospitals are a major application segment in the blood screening and typing market, using blood screening technologies to ensure safe and accurate transfusions for patients. Blood typing and pathogen screening are critical in hospitals, particularly in emergency situations, surgeries, and for patients requiring blood transfusions. The need for reliable, fast, and accurate blood screening tools is increasing as hospitals work to minimize transfusion-related complications. As hospitals continue to adopt advanced screening technologies, the market for blood screening and typing tools is expected to expand. Hospitals are expected to invest in automation and high-throughput systems to improve the efficiency and safety of blood testing.

Regional Outlook

The blood screening and typing market is growing across various regions, with North America, Europe, and Asia-Pacific leading the way in terms of demand for advanced blood testing technologies. North America has a strong market presence due to its advanced healthcare infrastructure and strict safety regulations. Europe is also experiencing growth, particularly in countries with well-established healthcare systems like Germany, the UK, and France. Asia-Pacific is expected to see significant growth due to the rising healthcare investments and increasing awareness of blood safety. The Middle East & Africa region is also expanding as infrastructure development and healthcare access improve, contributing to market growth.

North America

North America remains a leading market for blood screening and typing technologies, driven by the region’s advanced healthcare infrastructure, regulatory standards, and high demand for blood safety. The U.S. is the largest market in the region, with hospitals, reference laboratories, and blood banks adopting advanced technologies like nucleic acid amplification and immunohematology. The increasing incidence of blood-borne diseases and the need for safer blood donations are contributing to the growth of this market. Additionally, strict regulations on blood safety in North America ensure the continued demand for advanced screening and typing technologies, making it a key region for market growth.

Europe

Europe is a significant market for blood screening and typing technologies, with countries such as Germany, the UK, and France leading in the adoption of advanced blood safety measures. The region has well-established healthcare systems, with hospitals, reference laboratories, and blood banks adopting modern blood screening technologies to meet the growing demand for safe blood transfusions. The rising number of blood donations and the increasing focus on blood safety standards are driving the market’s growth. Additionally, Europe’s regulatory focus on ensuring the safety of blood products is contributing to the demand for advanced screening techniques, further supporting market expansion.

Asia-Pacific

Asia-Pacific is witnessing rapid growth in the blood screening and typing market, driven by rising healthcare investments and increasing awareness of blood safety. Countries like China, India, and Japan are expanding their healthcare infrastructure, creating demand for blood screening technologies in hospitals, blood banks, and reference laboratories. The prevalence of blood-borne diseases, such as hepatitis and HIV, is a major factor driving the adoption of blood screening technologies in the region. The growing middle class and the increasing demand for high-quality healthcare are further fueling the demand for advanced blood screening tools, positioning Asia-Pacific as a key region for market growth.

Middle East & Africa

The Middle East & Africa region is experiencing moderate growth in the blood screening and typing market, driven by expanding healthcare infrastructure and increasing demand for blood safety. Countries in the Middle East, such as the UAE and Saudi Arabia, are investing heavily in healthcare development, driving the need for advanced blood screening and typing technologies. In Africa, the demand for blood safety solutions is increasing, particularly in countries like South Africa and Nigeria, where the prevalence of blood-borne diseases is high. As healthcare access improves and infrastructure develops, the Middle East & Africa region is expected to see continued growth in the adoption of blood screening technologies.

Key Players COMPANIES PROFILED

• Abbott Laboratories
• Agena Bioscience
• Axo Science
• Bag Health Care Gmbh
• Becton, Dickinson
• Bio-Rad Laboratories
• Biomerieux
• Danaher
• Day Medical
• Diagast
• F. Hoffmann-La Roche
• Grifols
• Immucor
• Novacyt Group
• Ortho Clinical Diagnostics
• Quotient
• Siemens Healthcare
• Thermo Fisher Scientific

Top Companies having highest share

• Thermo Fisher Scientific: Holds approximately 25% of the market share.
• Bio-Rad Laboratories: Accounts for about 20% of the market share.

Investment Analysis and Opportunities

The blood screening and typing market offers substantial investment opportunities driven by advancements in diagnostic technologies and increasing healthcare needs worldwide. In 2024, the market is expected to see significant growth in the demand for Nucleic Acid Amplification Technology (NAT), which accounts for approximately 70% of the market share due to its ability to detect viral infections at early stages. Immunohematology is also expanding and is expected to represent around 20% of the market share, as it plays a vital role in blood typing and compatibility testing. The remaining 10% of the market share is attributed to microbiological screening techniques, primarily used for testing platelet concentrates. Geographically, North America remains the largest market, holding about 40% of the global market share, followed by the Asia-Pacific region at 30%, which is seeing rapid growth in demand due to increasing healthcare investments and infrastructure development. Opportunities lie in expanding product offerings, especially in emerging regions where access to blood screening technologies is still developing. The growing trend of personalized healthcare also presents opportunities for more tailored blood screening and typing solutions. Investment in research and development focused on improving the accuracy, speed, and cost-effectiveness of these tests is expected to drive market growth further.

New Product Development

In recent years, product development in the blood screening and typing market has been focused on enhancing the accuracy, speed, and safety of diagnostic methods. Approximately 60% of new products introduced in 2023 and 2024 were based on Nucleic Acid Amplification Technology (NAT), aimed at improving the sensitivity of blood screening. Additionally, 25% of new products targeted improvements in immunohematology techniques, particularly for rapid blood typing and cross-matching, to ensure safer blood transfusions. Around 15% of new products focused on microbiological techniques, designed to better detect pathogens in blood products, enhancing overall safety. Innovations also include the integration of automation into these products, making them more efficient and reducing human error. The trend toward user-friendly, automated systems has led to a 20% increase in product offerings, aimed at reducing the manual workload in reference laboratories and blood banks. Furthermore, there is a growing focus on developing cost-effective, high-throughput systems for large-scale applications in hospitals and standalone blood banks. With these developments, the market is expected to witness increased adoption of high-precision and reliable blood screening and typing products, catering to diverse healthcare needs.

Recent Developments 

• Thermo Fisher Scientific introduced a new blood screening system in early 2024, featuring enhanced NAT capabilities that increased detection efficiency by 20%, contributing to a 15% growth in adoption across reference laboratories.
• Bio-Rad Laboratories launched a new automated blood typing system in late 2023, which improved test turnaround time by 10% and gained a 12% increase in market share within standalone blood banks.
• Grifols released an upgraded version of their immunohematology testing reagent in early 2024, enhancing the accuracy of cross-matching in hospitals, leading to a 9% increase in product demand.
• Ortho Clinical Diagnostics introduced a next-generation blood screening platform in mid-2023, incorporating improved pathogen detection technology, resulting in a 7% increase in sales across hospitals and blood banks.
• Roche Diagnostics launched a new microbiological screening test for blood products in late 2023, contributing to a 6% rise in their overall market share due to enhanced safety features for platelet concentrates.

Report Coverage

This report provides a comprehensive analysis of the blood screening and typing market, including key segments based on types such as Nucleic Acid Amplification Technology (NAT), Immunohematology, and Microbiological Techniques. The market is divided into applications such as reference laboratories, standalone blood banks, and hospitals, with reference laboratories leading the demand, accounting for around 30% of the market share in 2024. North America remains the dominant region, holding about 40% of the market share due to advanced healthcare infrastructure and stringent safety regulations. The Asia-Pacific region is showing rapid growth and is expected to contribute 30% to the market share by 2033. The report also explores market dynamics such as increasing demand for safer and more accurate blood screening methods, particularly in light of rising healthcare needs and the growing number of blood transfusions worldwide. Additionally, it highlights the competitive landscape, focusing on the top players in the market, such as Thermo Fisher Scientific, Bio-Rad Laboratories, and Roche Diagnostics, which are driving innovation through new product developments and technological advancements. Key trends, including automation, cost-effectiveness, and integration with digital health technologies, are expected to continue shaping the market in the coming years.